Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.41 USD
-0.02 (-1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Marinus Pharmaceuticals, Inc. [MRNS]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
All Rise: Our Comprehensive Preview of the RAISE Readout, A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pivotal Year for Marinus with Key Readouts as RAISE Looms on the Horizon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Pivotal Year Gets Off to a Strong Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Takeaways Following AES; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
AES Shows Strong Interest in Ganaxolone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for MRNS 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Next Generation Ganaxolone Achieves Key Goals; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
5 Takeaways From the Marinus Analyst Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy Keeps Shining While RSE Analysis Sees Modest Delay; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from our Conversation with Marinus Pharmaceuticals Management; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Focus Turns to RAISE Though Ztalmy Continues to Make Gains; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy to Ztay on an Upward Trajectory During 2023, All Eyes Turn to RAISE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy Launch Continues to Gain Momentum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways From Marinus AES Investor Event; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy Off to a Nice Start; Reiterate Buy, Price Target Down to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ganaxolone Approval A Key Milestone With Resources to See Through Development Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ztalmy Approval Heralds the Start of Good Things; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D